Clinical Trial Update: Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization [Phase 2, Phase 3]

View source ↗

Summary

Prospective phase 2/3 study evaluating subconjunctival bevacizumab (Avastin) for corneal neovascularization; trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Neovascularization

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: Asociación para Evitar la Ceguera en México | Conditions: Corneal Neovascularization | Phase 2, Phase 3 | Status: COMPLETED